Cooperative Agreement R43IP001107

This Project Grant award of $458,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a VP4-based pseudovirus nanoparticle rotavirus vaccine for oral immunization. The award will fund research to create a non-replicating rotavirus vaccine candidate called S-VP4E, which consists of a calicivirus inner shell and multiple rotavirus spikes (VP4E) on the surface. This...

This federal Project Grant award of $883,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a thermostable measles fusion (F) glycoprotein vaccine strategy. The key objectives are to engineer a thermostable measles F protein immunogen and evaluate the protective immune responses it elicits, with the goal of creating a vaccine that is safe and effective for...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $242,250.00 to researchers at the University of Virginia to develop a vaccine against cryptosporidiosis, a common cause of diarrheal disease in sub-Saharan Africa and Asia. The goal is to create a liposomal vaccine formulation that stimulates both cellular and humoral immunity targeting the extracellular and intracellular life stages of the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $547,988 Project Grant to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025. The funding supports the development and testing of a novel monkeypox vaccine based on a replication-inducible version of the ACAM2000 smallpox vaccine. The proposed vaccine aims to retain the immunogenicity of ACAM2000 while reducing adverse side effects, particularly for...

This NSF Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Invvax, Inc. provides $996,606.00 in funding from July 1, 2025 to June 30, 2027 to develop stable prophylactic antibodies (SPABs) as long-term preventative treatments for infectious diseases. The project aims to discover antibody mutations that significantly enhance stability, extending their lifespan from weeks to years. The initial focus is on influenza, with the goal of creating SPABs that could...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel multivalent mucosal vaccines for human noroviruses. The total funding is $798,173 with a project period from May 1, 2025 to April 30, 2030. The key products and services to be delivered include: 1) Developing multivalent, live-vectored mucosal norovirus vaccines using FDA-approved rotavirus (RotaTeq)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $306,347 to Sunflower Therapeutics PBC to develop a first-in-class automated, continuous cell disruption method integrated with a continuous cell culturing bioreactor platform for virus-like particle (VLP) vaccine manufacturing. The goal is to simplify the VLP vaccine manufacturing process to lower the cost of goods manufactured (COGM) and...

This $304,742 Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel low-cost intradermal delivery platform for nucleic acid vaccines. The project aims to create a handheld pen device that can deliver electrical pulses through microelectrodes to create temporary pores in skin cells, allowing direct vaccine delivery to immune cells without the need for lipid nanoparticles (LNPs) or...